These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11674879)

  • 21. Confirmation of the efficacy of ERr 731 in perimenopausal women with menopausal symptoms.
    Kaszkin-Bettag M; Ventskovskiy BM; Solskyy S; Beck S; Hasper I; Kravchenko A; Rettenberger R; Richardson A; Heger PW
    Altern Ther Health Med; 2009; 15(1):24-34. PubMed ID: 19161045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Indications critically evaluated: hormone-domain hot flashes].
    MMW Fortschr Med; 2003 Nov; 145(46):5-8. PubMed ID: 14699822
    [No Abstract]   [Full Text] [Related]  

  • 24. Isoflavone treatment for acute menopausal symptoms.
    Cheng G; Wilczek B; Warner M; Gustafsson JA; Landgren BM
    Menopause; 2007; 14(3 Pt 1):468-73. PubMed ID: 17290160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose transdermal estradiol for symptomatic perimenopause.
    Shulman LP; Harari D
    Menopause; 2004; 11(1):34-9. PubMed ID: 14716180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised, double-blind, placebo-controlled trial on the effect of Pycnogenol on the climacteric syndrome in peri-menopausal women.
    Yang HM; Liao MF; Zhu SY; Liao MN; Rohdewald P
    Acta Obstet Gynecol Scand; 2007; 86(8):978-85. PubMed ID: 17653885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new synthetic estrone derivative for the treatment of climacteric disorders].
    Cyran W
    Med Welt; 1979 Mar; 30(10):384-8. PubMed ID: 368495
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
    Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
    Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Continuous graduated sequential therapy with estrogen-gestagen in the climacteric. A double-blind study].
    Jess P; Beck H; Gjorup PA; Andersen B; Helles A
    Ugeskr Laeger; 1976 Mar; 138(14):864-8. PubMed ID: 772902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.
    Westhoff C; Osborne LM; Schafer JE; Morroni C
    Obstet Gynecol; 2005 Jul; 106(1):89-96. PubMed ID: 15994622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy?
    Shulman LP
    J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo.
    Poindexter A; Reape KZ; Hait H
    Contraception; 2008 Aug; 78(2):113-9. PubMed ID: 18672111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural and synthetic oestrogens in the female climacteric.
    Practitioner; 1977 Apr; 218(1306):573-9. PubMed ID: 323841
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women.
    Wihlbäck AC; Nyberg S; Bäckström T; Bixo M; Sundström-Poromaa I
    Psychoneuroendocrinology; 2005 Jan; 30(1):38-50. PubMed ID: 15358441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
    Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2001 Oct; 15(5):349-58. PubMed ID: 11727357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative performance of a combined injectable contraceptive (50 mg norethisterone enanthate plus 5mg estradiol valerate) and a combined oral contraceptive (0.15 mg levonorgestrel plus 0.03 mg ethinyl estradiol) in adolescents.
    Molina RC; Sandoval JZ; Montero AV; Oyarzún PG; Molina TG; González EA
    J Pediatr Adolesc Gynecol; 2009 Feb; 22(1):25-31. PubMed ID: 19232299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.